FDA’s Project Optimus aims to transform early cancer researchNovember 14, 2023AMLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Multiprong strategy makes clinical trials less WhiteJune 23, 2023Breast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMelanomaAML
CBSM phone app eases anxiety, depression in cancer patientsJune 23, 2023Breast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell DisordersMelanoma
Huge underuse of germline testing for cancer patientsJune 22, 2023Breast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell DisordersMelanoma
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get medsJune 22, 2023Breast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell DisordersMelanoma
Widespread carboplatin, cisplatin shortages: NCCN surveyJune 9, 2023Lung CancerBreast CancerGenitourinary CancerMixed TopicsLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationHead & Neck/Thyroid Cancers
